GOSS stock news · Gossamer Bio
Get alerts for GOSS
Follow Gossamer Bio (GOSS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for GOSS12 health care companies saw big changes in their stock prices after the market closed on Friday.
NeutralGossamer Bio shares fell about 5% to $10.36 after hours. The report gives no new business news, so its business outlook remains unchanged.
12 health care companies saw big changes in their stock prices after the market closed on Friday.
NeutralThe report says Gossamer Bio shares fell 5.3%, but gives no business update to explain the move. It does not change the company's business outlook.
On Friday evening, 12 health care stocks saw big changes in their prices.
NeutralGossamer Bio stock increased 6.33% to $11.41 after-market. The report contains no operational or financial news, so it does not change Gossamer's prospects.
Gossamer Bio's stock drops as $250 million funding relies on FDA achievement benchmarks.
Bad for GOSSGossamer Bio's shares declined as investors reacted to a $250 million financing deal that is heavily dependent on FDA milestones for its drug seralutinib. The financing structure raises concerns about dilution and the company's reliance on regulatory approval, impacting investor sentiment negatively.
Gossamer Bio, Inc. finalizes a significant definitive agreement (GOSS).
Good for GOSSGossamer Bio's filing of a Form 8-K regarding a material definitive agreement suggests a pivotal development that could enhance its business strategy and investor confidence, warranting immediate attention from the market.